Also, the odds of having calcinosis increased by 8% (CI 4%, 11%) for each year since diagnosis. The specificity of the model was high (correctly classifying a patient who did not have calcinosis 91% of the time), but the sensitivity was relatively low, correctly classifying a patient who did have calcinosis only 35% of the time. Conclusion: In a cohort of patients with SSc attending a tertiary centre, history of surgical debridement, positive anticentromere antibody and disease duration were predictors of calcinosis. However, the low sensitivity of a multiple regression model suggests there are other important predictors of calcinosis that have not been accounted for in this analysis. Background: IL6 is implicated in activation of extracellular matrix (ECM) in scleroderma (SSc) fibroblasts and via its interplay with chemokines may modulate mononuclear cell recruitment. We have explored the role of IL6 in macrophage differentiation in SSc and its regulation of fibrotic response Methods: Peripheral blood mononuclear cells (PBMCs) were isolated from patients with early stage diffuse cutaneous SSc (dcSSc) (n ¼ 12) and healthy controls (n ¼ 6). Dermal fibroblasts were cultured from skin biopsies from healthy controls (n ¼ 4) and dcSSc (n ¼ 4). Flow cytometry was used to quantify alternatively activated M2 macrophages in PBMCs defined by CD68 þ
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þ cells. A magneticactivated cell sorting (MACS) based protocol was used to select CD14 þ cells. CD14 þ Cells were stimulated for 7 days with M-CSF before further stimulation with M-CSF alone or with IL6/sIL6R. Flow cytometry was then used to determine the effect of IL6 trans-signalling on macrophage polarization. Control fibroblasts were stimulated with conditioned media (CM) from cultured M2 macrophages. Western blot analysis for Collagen type-1 (Col-1) and alpha smooth muscle actin (aSMA) were used to assess ECM levels induced by CM and the effect of CM on fibroblast contractile response was evaluated with a collagen gel contraction assay. Results: PMBCs were isolated from healthy controls (n ¼ 6) mean age (37 AE 13.8 months), and dcSSc patients (n ¼ 12), mean age (42.2 AE 15.6) and disease duration (34.2 AE 15.6). Flow cytometry of PBMCs quantified (mean AE SEM %) subpopulation of M2 macrophages (9.3 AE 0.3%) and (1.4 AE 1.2%) P ¼ 0.0087 in SSc patients compared with controls respectively, with SSc M2 macrophages significantly higher compared with controls . Stimulation of isolated macrophages with IL6/sIL6R polarized the M2 macrophage population by (4-fold, P < 0.02) and (1.6-fold, P < 0.04) in control and SSc macrophages respectively. CM generated from SSc M2 macrophages led to increased ECM proteins aSMA (3-fold, P < 0.04) and Col-I (3.2-fold, P < 0.04) compared with control macrophages in the presence of control fibroblasts. CM from SSc M2 macrophages induced contraction of control fibroblasts leading to (4mmAE0.3, P < 0.05) reduction in collagen gel diameter compared with control CM. Conclusion: Our results indicate alternatively activated macrophage phenotype in early stage scleroderma may partly be polarized by IL-6 trans-signalling. This supports the critical role of distinct macrophage subpopulation in regulation of myofibroblastic differentiation and contractile response in SSc. Elucidating these pathways may lead to better understanding of pathogenesis and new options for therapy. Results: Although diffuse cutaneous subset (dcSSc) was associated with significantly worse survival compared with the limited cutaneous subset (lcSSc) with 5, 10 and 15 year survival of 86%, 72% and 55% v 94%, 82% and 69% respectively, P ¼ 0.017, presence of organ-based complications was associated with a substantial increase in mortality in both subsets. In fact, survival rates were very similar for lcSSc and dcSSc patients with organ involvement (88% and 86% at 5, 67% and 68% at 10 and 47% and 43% at 15 years respectively). Although dcSSc patients had similar mortality rates over the first 5 years of disease (86%), whether or not major organ involvement had been identified, later mortality rates decreased and by the end of follow-up their survival was similar to that of lcSSc patients with no organ complications (76% and 81% at 15 years). Univariable Cox regression demonstrated that skin score (HR 1.02), dcSSc subset (HR 1.5), lung function tests-FVC, DLCO and KCO (HR 0.99, 0.97 and 0.99), age at disease onset (HR 1.05), haemoglobin (HR 0.76), ESR (HR 1.02) and creatinine (HR 1.003) strongly predicted survival. In addition, cardiac SSc, pulmonary hypertension, clinically significant pulmonary fibrosis and renal crisis development within 3 years from onset were associated with HRs of 5.4, 6.9, 2.4 and 2.4 respectively. Although SSc hallmark autoantibodies strongly associate with organ disease, the only specificity that significantly predicted survival was anticentromere (HR 0.6), which lost its significance when included into a multivariable model. The model that was initially derived in the 1995-1999 cohort was subsequently tested and updated in the 2000-2003 cohort. The covariates that remained significant independent predictors of survival were age at disease onset>60 years (HR 3.1), diffuse subset (HR 1.5), DLCO<65% (HR 2) and presence of PH (HR 4.4) or renal crisis (HR 1.9) within the first 3 years of disease. Model calibration was excellent, although discriminatory performance remained moderately good (AUC 0.72). Conclusion: Although SSc specific antibodies predict pattern of organ disease in SSc patients, they do not associate with survival independently. Subset and organ-based complications are better predictors of mortality and this may reflect disease severity. Background: SSc and sarcoidosis are both uncommon CTDs with reported prevalence of about 3.08 in 100 000 and 20 in 100 000 respectively. Case reports and a recent review suggest an association between the two diseases as well as the possibility that the CTD may trigger granulomatous inflammation. We evaluated the prevalence and clinical features of patients with both these diseases. Methods: We retrospectively examined the clinical database of all SSc patients (n % 2500) in our centre over the last 12 years.
Results: We identified a sub-cohort of 827 patients. From these, 11 patients (1.33%) were found to have both SSc and sarcoidosis, 8 of which are female. Nine patients had limited cutaneous SSc. The median age was 63.0 AE 11.2 (years AE S.D.). The majority (63.7%) were Caucasians. The diagnosis of sarcoidosis preceded SSc in 7 patients and was contemporaneous in one patient. The median interval for diagnosis between the two diseases was 14.0 AE 11.4 years. All patients, but one, were anti-nuclear antibodies (ANA) positive with homogenous pattern identified in 5 patients (45.5%) and centromere pattern in 4 (36.4%). Extra-nuclear antibodies (ENA) were positive in 5 patients, mainly anti-Scl70 (36.4%). Sarcoidosis was biopsy proven in 5 patients, one had a positive Kveim test and 5 were considered to have sarcoidosis based on clinical features and supportive investigations. Five patients had single-organ involvement related to sarcoidosis (lung, lacrimal gland, lymph nodes). Interstitial lung disease (ILD) was present in 5 patients (45.5%), a majority of these harboured antiScl70 antibodies. 60% of these had radiological changes attributable to both diseases and the remaining 2 patients had changes related to SSc or sarcoidosis alone. Three of the patients with ILD required immunosuppression. Apart from two patients who developed pulmonary arterial hypertension and one with suspected cardiac sarcoidosis, no other major organ involvement was documented.
Conclusion:
The data suggest that the observed prevalence for coexisting diseases is higher than expected. Interestingly, the gender preponderance is more similar to that observed in SSc than sarcoidosis. In contrast to recent review, a majority in this cohort had sarcoidosis prior to SSc suggesting that it is less likely that SSc may be associated with granulomatous formation. The pulmonary involvement shared between the two diseases is consistent with the concept of similar aetiopathogenesis for SSc and sarcoidosis. Disclosure statement: The authors have declared no conflicts of interest. Methods: MRTF-A knockout (KO) and wild type (WT) control mice were subjected to excisional wounding (4 mm punch biopsy, basal wound area 12.6 mm 2 ). MRTF-A signal transduction was studied in healthy control and SSc fibroblasts cultured on reduced mechanical stress collagen gels (Softwell 0.5 kPa). The small molecule inhibitor CCG1423 was used to antagonize MRTF-A signalling. SSc fibrosis responses were modelled by collagen gel contraction, CTGF, and type I collagen synthesis. MRTF-A signalling was assayed by Western blotting of nuclear and cytoplasmic extracts. Results: Following excisional wounding MRTF-A KO mice wounds failed to close normally and increased in size during days 1-7, wound area decreasing by day 11. When compared with wild type controls, MRTF-A KO wounds were enlarged at day 7 (WT area 6 mm 2 , KO area 12.4 mm 2 , P < 0.03), and day 11 (WT area 0.42 mm 2 , KO area 3.4 mm 2 , P < 0.01). The histology of Day 11 skin wounds showing reduced scar formation and abnormal vessels, which were dilated, and exhibited extravasation of red blood cells. Gel contraction by WT fibroblasts was enhanced by TGFb and blocked by CCG1423 1 mM (basal conditions mean gel mass 0.176 g, TGFb treated 0.118 g, TGFb þ CCG1423 0.238g, P < 0.002). Dermal fibroblasts from MRTF-A KO mice showed reduced basal gel contraction, and impaired response to TGFb,(basal conditions mean gel mass 0.349 g, TGFb treated 0.259 g, TGFb þ CCG1423 0.313 g (P < 0.05 basal vs wild type). SSc fibroblasts showed enhanced basal CTGF and type I collagen which was suppressed to normal levels by CCG-1423. On soft tissue culture substrates SSc fibroblasts but not control fibroblasts showed constitutive nuclear localization of MRTF-A, enhanced by TGFb. Conclusion: MRTF-A has a role in wound contraction and in new vessel formation during tissue repair. MRTF-A signalling is altered in SSc fibroblasts, present under basal conditions. Increased synthesis of pro-fibrotic proteins by SSc fibroblasts is dependent on the MRTF-A pathway. CCG1423 and its derivatives may be potential anti-fibrotics to benefit SSc fibrosis. Disclosure statement: The authors have declared no conflicts of interest. Background: Stem cell factor (SCF) is a candidate factor implicated in the development of SSc and possible therapeutic target. SCF is a cytokine which acts via c-Kit, a tyrosine kinase receptor, present on the surface of progenitor cells, mast cells, and melanocytes. This relationship with mast cells potentially drives pruritus, a significant clinical problem in SSc, and an important sign of disease activity. The hallmark hyperpigmentation of affected skin in SSc may also reflect SCF/c-Kit dependent activation of melanocytes. In migrating fibroblasts, c-Kit was found to be up-regulated. Here, we measure the activity of SCF/c-Kit pathway in SSc and test the potential of SCF as a chemo-attractant for SSc fibroblasts. In addition we examine correlation between SCF levels and severity of pruritus and increased skin pigmentation.
INVESTIGATING THE ROLE OF MRTF-A IN SYSTEMIC SCLEROSIS

THE ROLE OF STEM CELL FACTOR AND c-Kit IN PATIENTS WITH SYSTEMIC SCLEROSIS
Methods: Blister fluid, tissue and plasma samples were harvested from healthy controls and SSc patients. Collation of data including pruritus and pigmentation scores was also obtained. Migration was assessed using the scratch wound assay and transwell migration. The expression and quantity of SCF and c-Kit in SSc and control plasma, blister fluid, and conditioned media was assessed by ELISA. Results: SCF expression was enhanced in SSc epidermis samples by qPCR (566 vs 336 corrected copy numbers respectively). Transwell migration showed dose dependent response for rSCF with 350 migrating SSc lung fibroblasts at a concentration of 100 ng/ml, 315 cells at 10 ng/ml, 307 cells at 5 ng/ml, 241 cells at 2.5 ng/ml, 234 cells for negative control and 336 cells for positive control (PDGF-BB 10 ng/ml) after 4 hours incubation, suggesting that SCF acts as a chemoattractant. In contrast, ELISA data showed a decrease of soluble c-kit expression in plasma of SSc patients compared with healthy controls (13.9 ng/ml and 19.6 ng/ml respectively P ¼ 0.03), whereas plasma SCF expression was not significantly altered in SSc (1221.2 pg/ml SSc and 1325 pg/ml for healthy control P ¼ 0.36). In addition, a reduction was observed of SCF levels in SSc blister fluids compared with healthy controls (1223 pg/ml and 1414 pg/ml, P ¼ 0.29, while in fibroblast conditioned media, SCF showed a trend to be increased (152 pg/ml) compared with controls (130 pg/ml) P ¼ 0.002. Conclusion: Although SCF mRNA is elevated in the epidermis of SSc subjects, there was no significant difference in the level of SCF protein or soluble c-kit in plasma, or blister fluid. If SCF/c-Kit expression is directly related to disease activity, studying a subgroup with untreated active disease may be more definitive. There is evidence that SCF is being released by SSc fibroblasts and is capable of promoting migration of these cells. Further work is required to elucidate the potential role of SCF in pathogenesis and its ability to drive pruritus, a neglected but important symptom of this challenging disease. Background: Clinical diversity in SScis likely to reflect multifaceted pathogenesis and the effect of key growth factors or cytokines operating within a disease-specific microenvironment. Dermal interstitial fluid sampling offers the potential to examine local biological mechanisms and define protein expression within lesional tissue. We have used multiplex cytokine analysis to define the inflammatory and immune activity in the lesions of SSc patients. Methods: Interstitial fluid samples from the forearm skin of patients (n ¼ 25; DcSSc ¼ 19; LcSSc ¼ 6) or healthy controls (HC) (n ¼ 10) were collected using a dermal suction blister method, together with contemporaneous serum samples. Both the serum and interstitial fluid samples were profiled by Luminex array for inflammatory cytokines, chemokines, and growth factors. Permutation analysis was used to compare cytokine levels in SSc and HC samples, as well as to compare the difference between serum samples and healthy control samples. Pearson's correlation coefficient was used to assess
